Safety and Efficacy of Magnesium Sulphate as an Adjuvant to Levobupivacaine in Ultra-sound Guided Transversus Abdominis Plan Block in Pediatric Abdominal Cancer Surgery

• Status: Recruiting
• Trial end date: 2021-05-01
• Target enrollment: 0
• Participant gender: All

Summary

To study the efficacy and safety of magnesium sulphate as adjuvant to levobupivacaine in transversus abdominis plane (TAP) block in children undergoing abdominal cancer surgery.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: South Egypt Cancer Institute
• Treatments: Levobupivacaine; Magnesium Sulfate

Criteria

Inclusion Criteria:

• patients with American society of anesthesiology (ASA) Ӏ and ӀӀ physical status, aged from 1 to 7 years old and their weight 10 to 30 Kg of both sex will undergo abdominal cancer surgery will be enrolled.

Exclusion Criteria:

• Children with local infection, hemorrhagic disorders, drug hypersensitivity or allergy to the studied drugs, muscular disorders, central and peripheral neuropathy, significant organ dysfunction, cardiac dysrrhythmia, congenital heart diseases and unconscious or mentally retarded patients will be excluded from this study.